393 related articles for article (PubMed ID: 32083290)
1. Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma.
Motoi F; Unno M
Jpn J Clin Oncol; 2020 May; 50(5):483-489. PubMed ID: 32083290
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
Labori KJ; Lassen K; Hoem D; Grønbech JE; Søreide JA; Mortensen K; Smaaland R; Sorbye H; Verbeke C; Dueland S
BMC Surg; 2017 Aug; 17(1):94. PubMed ID: 28841916
[TBL] [Abstract][Full Text] [Related]
3. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer.
Klaiber U; Leonhardt CS; Strobel O; Tjaden C; Hackert T; Neoptolemos JP
Langenbecks Arch Surg; 2018 Dec; 403(8):917-932. PubMed ID: 30397779
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
Front Oncol; 2020; 10():41. PubMed ID: 32083002
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma.
Paiella S; Malleo G; Simoni N; Micera R; Guariglia S; Cavedon C; Marchegiani G; Esposito A; Landoni L; Casetti L; Tuveri M; Milella M; Secchettin E; Manzini G; Bovo C; De Pastena M; Fontana M; Salvia R; Mazzarotto R; Bassi C
BMC Cancer; 2021 Feb; 21(1):165. PubMed ID: 33593311
[TBL] [Abstract][Full Text] [Related]
7. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.
Abbott DE; Tzeng CW; Merkow RP; Cantor SB; Chang GJ; Katz MH; Bentrem DJ; Bilimoria KY; Crane CH; Varadhachary GR; Abbruzzese JL; Wolff RA; Lee JE; Evans DB; Fleming JB
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S500-8. PubMed ID: 23397153
[TBL] [Abstract][Full Text] [Related]
9. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].
Scheufele F; Friess H
Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy for pancreatic cancer.
Springfeld C; Jäger D; Büchler MW; Strobel O; Hackert T; Palmer DH; Neoptolemos JP
Presse Med; 2019 Mar; 48(3 Pt 2):e159-e174. PubMed ID: 30879894
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).
Motoi F; Kosuge T; Ueno H; Yamaue H; Satoi S; Sho M; Honda G; Matsumoto I; Wada K; Furuse J; Matsuyama Y; Unno M;
Jpn J Clin Oncol; 2019 Feb; 49(2):190-194. PubMed ID: 30608598
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
[TBL] [Abstract][Full Text] [Related]
13. Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749).
Tachezy M; Gebauer F; Petersen C; Arnold D; Trepel M; Wegscheider K; Schafhausen P; Bockhorn M; Izbicki JR; Yekebas E
BMC Cancer; 2014 Jun; 14():411. PubMed ID: 24906700
[TBL] [Abstract][Full Text] [Related]
14. [Adjuvant Chemotherapy after Surgery for Pancreatic Cancer].
Furuse J
Gan To Kagaku Ryoho; 2016 Feb; 43(2):160-4. PubMed ID: 27067680
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant therapy for resectable pancreatic cancer.
Raut CP; Evans DB; Crane CH; Pisters PW; Wolff RA
Surg Oncol Clin N Am; 2004 Oct; 13(4):639-61, ix. PubMed ID: 15350939
[TBL] [Abstract][Full Text] [Related]
16. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?
Reni M
World J Gastroenterol; 2010 Oct; 16(39):4883-7. PubMed ID: 20954273
[TBL] [Abstract][Full Text] [Related]
18. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.
Greer SE; Pipas JM; Sutton JE; Zaki BI; Tsapakos M; Colacchio TA; Gibson JJ; Wiener DC; Ripple GH; Barth RJ
J Am Coll Surg; 2008 Mar; 206(3):451-7. PubMed ID: 18308215
[TBL] [Abstract][Full Text] [Related]
19. Current standards and new innovative approaches for treatment of pancreatic cancer.
Conroy T; Bachet JB; Ayav A; Huguet F; Lambert A; Caramella C; Maréchal R; Van Laethem JL; Ducreux M
Eur J Cancer; 2016 Apr; 57():10-22. PubMed ID: 26851397
[TBL] [Abstract][Full Text] [Related]
20. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]